KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kailera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.43+0.18 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.6%
116M of 130M shares
Institutional holders
99
99 new, 0 sold out
Net institutional buying
116M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $326.75M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CPP Investment Board Private Holdings (4) Inc. | 7,304,688 | 5.60% | 13G (passive) | Jun 30, 2026 |
| BCPE Perseus Investor, LP | 26,255,581 | 20.27% | 13D (active) | Apr 16, 2026 |
| BCLS Fund IV Investments, L.P. | 22,583,268 | 17.43% | 13D (active) | Apr 16, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 11,511,853 | 8.90% | 13G (passive) | Jun 30, 2026 |
| RTW Investments, LP | 10,776,820 | 8.30% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KLRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 26,255,581 | 20.25% | $578.41M | New | 12.01% |
| Bain Capital Life Sciences Investors, LLC | 22,583,268 | 17.42% | $497.51M | New | 29.58% |
| Rtw Investments, LP | 10,776,820 | 8.31% | $237.41M | New | 2.03% |
| Canada Pension Plan Investment Board | 7,304,688 | 5.63% | $160.92M | New | 0.09% |
| Atlas Venture Life Science Advisors, LLC | 5,171,282 | 3.99% | $113.92M | New | 12.93% |
| FMR LLC | 3,970,865 | 3.06% | $87.48M | New | 0.00% |
| BlackRock, Inc. | 3,928,604 | 3.03% | $86.55M | New | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,534,410 | 2.73% | $77.86K | New | 0.01% |
| Citadel Advisors LLC | 3,240,787 | 2.50% | $71.39M | New | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 3,208,286 | 2.47% | $70.68M | New | 0.10% |
| Wellington Management Group Llp | 2,919,110 | 2.25% | $64.31M | New | 0.01% |
| Royalty Pharma Sub-Manager, LLC | 2,455,357 | 1.89% | $54.09M | New | 22.36% |
| Siren, L.L.C. | 2,214,286 | 1.71% | $48.78M | New | 0.99% |
| Vanguard Capital Management LLC | 1,693,958 | 1.31% | $37.32M | New | 0.00% |
| Vanguard Portfolio Management LLC | 1,652,507 | 1.27% | $36.40M | New | 0.00% |
| Geode Capital Management, LLC | 1,133,115 | 0.87% | $24.97M | New | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,100,000 | 0.85% | $24.23M | New | 0.53% |
| Farallon Capital Management LLC | 1,100,000 | 0.85% | $24.23M | New | 0.11% |
| Trails Edge Capital Partners, LP | 984,786 | 0.76% | $21.69M | New | 3.44% |
| UBS Group AG | 972,683 | 0.75% | $21.43M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 99 | 116M | 89.6% | 99 / 0 | 0 / 0 | 116M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KLRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,191,928 | 1.69% | $37.13M | 0.10% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,180,411 | 0.91% | $26.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,163,223 | 0.90% | $25.63M | 0.03% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 904,283 | 0.70% | $19.92M | 0.17% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 850,042 | 0.66% | $18.73M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 752,900 | 0.58% | $17.27M | 0.02% | May 31, 2026 |
| Columbia Small Cap Growth Fund | 652,308 | 0.50% | $14.96M | 0.41% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 635,206 | 0.49% | $13.99M | 0.14% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 619,399 | 0.48% | $14.21M | 0.27% | May 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 616,720 | 0.48% | $13.59M | 0.76% | Jun 30, 2026 |
| Fidelity Blue Chip Growth Fund | 587,097 | 0.45% | $9.95M | 0.01% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 503,961 | 0.39% | $8.54M | 0.03% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 487,994 | 0.38% | $10.75M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 476,221 | 0.37% | $10.49M | 0.01% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 464,174 | 0.36% | $10.65M | 0.18% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ronald C. Renaud JR | CEO & President, Director | 38,094 | 0.03% | Jun 11, 2026 |
| Nur Nicholson | Chief Technology Officer | – | – | Sep 9, 2026 |
| Kathleen Tregoning | See Remarks | – | – | Jul 8, 2026 |
| Paul D. Burgess | See Remarks | – | – | Apr 20, 2026 |
| Paula Cloghessy | Chief People Officer | – | – | Apr 20, 2026 |
| Jamie Beth Coleman | Chief Commercial Officer | – | – | Apr 20, 2026 |
| Scott Akamine | Chief Legal Officer | – | – | Apr 20, 2026 |
| Scott M. Wasserman | Chief Medical Officer | – | – | Apr 20, 2026 |
| Douglas W. Pagan | Chief Financial Officer | – | – | Apr 20, 2026 |
| Frank Clyburn | Director | – | – | Apr 20, 2026 |
| Christopher Hite | Director | – | – | Apr 20, 2026 |
| John F. Milligan | Director | – | – | Apr 20, 2026 |
| Martin Mackay | Director | – | – | Apr 20, 2026 |
| Adam Koppel | Director, 10% owner | 16,875,000 | 13.02% | Apr 20, 2026 |
| Andrew T. Kaplan | Director, 10% owner | 17,857,143 | 13.77% | Apr 20, 2026 |
| Yuting Liu | Director | – | – | Apr 16, 2026 |
| Roderick Wong | 10% owner | – | – | Apr 22, 2026 |
| Rtw Investments, Lp | 10% owner | 10,776,820 | 8.31% | Apr 22, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | 9,477,720 | 7.31% | Apr 22, 2026 |
| BCLS Fund IV Investments, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Capital Investors Llc Bain | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences IV General Partner, LLC | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Fund XIV, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital XIV General Partner, LLC | 10% owner | – | – | Apr 20, 2026 |
| BCPE Perseus Investor GP, LLC | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences Fund IV, L.P. | 10% owner | – | – | Apr 20, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | – | Apr 20, 2026 |
| BCPE Perseus Investor, LP | 10% owner | 26,255,581 | 20.25% | Apr 20, 2026 |
| BCLS Fund IV Investments GP, LLC | 10% owner | 21,020,768 | 16.21% | Apr 20, 2026 |
| Stuart Partners, LLC | 10% owner | – | – | Apr 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ronald C. Renaud JR CEO & President, Director | Jun 9, 2026 | Option exercise | +38,094 | $5.25 | $199.99K | 38,094 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Apr 20, 2026 | Conversion | +9,477,719 | – | – | 9,477,719 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Apr 20, 2026 | Conversion | +2,034,133 | – | – | 2,034,133 |
| Rtw Investments, Lp 10% owner | Apr 20, 2026 | Buy | +500,000 | $16.00 | $8.00M | 10,776,820 |
| Rtw Investments, Lp 10% owner | Apr 20, 2026 | Conversion | +10,276,820 | – | – | 10,276,820 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Conversion | +16,875,000 | – | – | 16,875,000 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 22,583,268 |
| Adam Koppel Director, 10% owner | Apr 20, 2026 | Conversion | +4,145,768 | – | – | 21,020,768 |
| Andrew T. Kaplan Director, 10% owner | Apr 20, 2026 | Conversion | +17,857,143 | – | – | 17,857,143 |
| Andrew T. Kaplan Director, 10% owner | Apr 20, 2026 | Buy | +8,398,438 | $16.00 | $134.38M | 26,255,581 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Conversion | +4,145,768 | – | – | 21,020,768 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 22,583,268 |
| BCLS Fund IV Investments GP, LLC 10% owner | Apr 20, 2026 | Conversion | +16,875,000 | – | – | 16,875,000 |
| BCPE Perseus Investor, LP 10% owner | Apr 20, 2026 | Buy | +8,398,438 | $16.00 | $134.38M | 26,255,581 |
| BCPE Perseus Investor, LP 10% owner | Apr 20, 2026 | Conversion | +17,857,143 | – | – | 17,857,143 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.